171 related articles for article (PubMed ID: 34625283)
1. The Health Care Resource Utilization and Costs Among Patients With Type 2 Diabetes and Either Cardiovascular Disease or Cardiovascular Risk Factors An Analysis of a US Health Insurance Database.
Meyers J; Hoog M; Mody R; Yu M; Davis K
Clin Ther; 2021 Nov; 43(11):1827-1842. PubMed ID: 34625283
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study.
Olufade T; Jiang L; Israni R; Huang J; Gosmanov AR
Diabetes Obes Metab; 2021 Dec; 23(12):2741-2751. PubMed ID: 34405521
[TBL] [Abstract][Full Text] [Related]
3. Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis.
Kangethe A; Lawrence DF; Touya M; Chrones L; Polson M; Evangelatos T
BMC Health Serv Res; 2021 Aug; 21(1):778. PubMed ID: 34362353
[TBL] [Abstract][Full Text] [Related]
4. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T
Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065
[TBL] [Abstract][Full Text] [Related]
5. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
[TBL] [Abstract][Full Text] [Related]
6. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
Nguyen C; Luthra R; Kuti E; Willey VJ
Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
[TBL] [Abstract][Full Text] [Related]
7. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel.
Melzer Cohen C; Hallén N; Chodick G; Bourvine L; Waner T; Karasik A
Value Health Reg Issues; 2020 Sep; 22():83-92. PubMed ID: 32798839
[TBL] [Abstract][Full Text] [Related]
8. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States.
Mody R; Meyers J; Yu M; Davis K; Levine JA
Curr Med Res Opin; 2022 Nov; 38(11):1785-1795. PubMed ID: 35758147
[TBL] [Abstract][Full Text] [Related]
9. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations.
Coutinho AD; Raju AD; Wang W; Stafkey-Mailey D; Shetty S; Sander SD
Curr Med Res Opin; 2018 Jun; 34(6):1005-1012. PubMed ID: 29378486
[TBL] [Abstract][Full Text] [Related]
10. Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: "INSIST" study.
Mohammedi K; Fauchier L; Quignot N; Khachatryan A; Banon T; Kapnang R; Kikuchi K; Ren H; Massien C; Vigié L; Larsen S; Sibon I
Cardiovasc Diabetol; 2024 May; 23(1):183. PubMed ID: 38812009
[TBL] [Abstract][Full Text] [Related]
11. Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study.
Shore AC; Colhoun HM; Natali A; Palombo C; Khan F; Östling G; Aizawa K; Kennbäck C; Casanova F; Persson M; Gooding K; Gates PE; Looker H; Dove F; Belch J; Pinnola S; Venturi E; Kozakova M; Goncalves I; Kravic J; Björkbacka H; Nilsson J;
Diabetes Care; 2018 Oct; 41(10):2212-2219. PubMed ID: 30061319
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular event costs in patients with Type 2 diabetes mellitus.
Johnston SS; Sheehan JJ; Shah M; Cappell K; Princic N; Smith D; Kalsekar I
J Med Econ; 2015; 18(12):1032-40. PubMed ID: 26189723
[TBL] [Abstract][Full Text] [Related]
13. Association of Ideal Cardiovascular Health and Long-term Healthcare Costs.
Willis BL; DeFina LF; Bachmann JM; Franzini L; Shay CM; Gao A; Leonard D; Berry JD
Am J Prev Med; 2015 Nov; 49(5):678-685. PubMed ID: 26141912
[TBL] [Abstract][Full Text] [Related]
14. Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia.
Punekar RS; Fox KM; Richhariya A; Fisher MD; Cziraky M; Gandra SR; Toth PP
Clin Cardiol; 2015 Aug; 38(8):483-91. PubMed ID: 26100722
[TBL] [Abstract][Full Text] [Related]
15. Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin.
Parker ED; Wittbrodt ET; McPheeters JT; Frias JP
Diabetes Obes Metab; 2019 Feb; 21(2):227-233. PubMed ID: 30101553
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of cardiovascular disease and risk factors among type 2 diabetes patients followed in a hospital setting in Portugal: The PICT2RE observational study.
Cardoso H; Tavares Bello C; Andrade L; Sobral do Rosário F; Louro J; Nogueira C; Rodrigues E; Vieira NB; Carqueja T;
Rev Port Cardiol; 2023 Apr; 42(4):319-330. PubMed ID: 36634764
[TBL] [Abstract][Full Text] [Related]
17. Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study.
Bernfort L; Husberg M; Wiréhn AB; Rosenqvist U; Gustavsson S; Karlsdotter K; Levin LÅ
Diabetes Ther; 2020 Jul; 11(7):1537-1549. PubMed ID: 32468515
[TBL] [Abstract][Full Text] [Related]
18. Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza.
Corral M; Castro RC; To TM; Arndorfer S; Wang S; Stephens J
J Med Econ; 2022; 25(1):1061-1067. PubMed ID: 35943115
[TBL] [Abstract][Full Text] [Related]
19. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database.
Al-Jedai AH; Almudaiheem HY; Alissa DA; Al-Enazy HS; Korayem GB; Alghamdi A; Alghamdi S
PLoS One; 2022; 17(10):e0273836. PubMed ID: 36264903
[TBL] [Abstract][Full Text] [Related]
20. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Kong AM; Farahbakhshian S; Pendergraft T; Brouillette MA; Mukherjee B; Smith DM; Sheehan JJ
Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
